Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
NCT02984644Phase 3Completed
- Sponsor
- UT Health San Antonio
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Change in Plasma Glucose Concentration and Change in Endogenous Glucose Production. Started Sep 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02984644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984644.